[bedast]

Significantly increasing production for a temporary benefit is going to require significant investment. Since it is a temporary benefit, it's probably not worth that significant investment. Because eventually the demand will falter.

And yeah, the weight loss benefit is a temporary benefit. It may last a few years, but it fades. This is not a new drug class. The weight loss aspect to it is also not new (Saxenda, the weight loss variant of Victoza, released in 2014). Liraglutide was in trials for weight management when I started Victoza. That was a decade ago. I'm on Mounjaro now for glycemic management and it works great for that. But it's not doing anything for appetite, delayed gastric emptying, etc.